AP971A - Use of raloxifene in preventing breast cancer. - Google Patents

Use of raloxifene in preventing breast cancer. Download PDF

Info

Publication number
AP971A
AP971A APAP/P/1999/001494A AP9901494A AP971A AP 971 A AP971 A AP 971A AP 9901494 A AP9901494 A AP 9901494A AP 971 A AP971 A AP 971A
Authority
AP
ARIPO
Prior art keywords
breast cancer
pharmaceutical formulation
human
term
raloxifene
Prior art date
Application number
APAP/P/1999/001494A
Other languages
English (en)
Other versions
AP9901494A0 (en
Inventor
Fredrick Jay Cohen
Robert Stephen Eckert
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP9901494A0 publication Critical patent/AP9901494A0/xx
Application granted granted Critical
Publication of AP971A publication Critical patent/AP971A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1999/001494A 1996-10-30 1997-10-29 Use of raloxifene in preventing breast cancer. AP971A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10
PCT/US1997/019779 WO1998018449A1 (en) 1996-10-30 1997-10-29 Methods of preventing breast cancer

Publications (2)

Publication Number Publication Date
AP9901494A0 AP9901494A0 (en) 1999-03-31
AP971A true AP971A (en) 2001-05-30

Family

ID=27268608

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001494A AP971A (en) 1996-10-30 1997-10-29 Use of raloxifene in preventing breast cancer.

Country Status (44)

Country Link
US (2) US6303634B1 (et)
EP (3) EP0839532B1 (et)
JP (2) JPH10147529A (et)
CN (2) CN1182590A (et)
AP (1) AP971A (et)
AR (2) AR010538A1 (et)
AT (2) ATE338551T1 (et)
AU (3) AU5005197A (et)
BE (2) BE1011382A5 (et)
BG (1) BG63841B1 (et)
BR (1) BR9712703A (et)
CA (2) CA2219070C (et)
CH (2) CH691847A5 (et)
CZ (2) CZ300261B6 (et)
DE (2) DE69721692T2 (et)
DK (2) DK1369115T3 (et)
EA (2) EA002054B1 (et)
EE (1) EE03663B1 (et)
ES (4) ES2135342B1 (et)
FR (2) FR2755014B1 (et)
GB (3) GB2318733A (et)
GE (1) GEP20032910B (et)
GR (2) GR1003189B (et)
HK (1) HK1010495A1 (et)
HU (2) HUP9701778A3 (et)
IE (2) IE970773A1 (et)
IL (2) IL122026A0 (et)
IS (1) IS5035A (et)
IT (2) IT1298470B1 (et)
LU (2) LU90157B1 (et)
LV (1) LV12353B (et)
MY (1) MY121623A (et)
NL (2) NL1007386C2 (et)
NO (2) NO974973D0 (et)
NZ (1) NZ329042A (et)
PT (2) PT839532E (et)
RO (1) RO120813B1 (et)
SG (2) SG72765A1 (et)
SI (3) SI0839532T1 (et)
SK (1) SK287047B6 (et)
TR (1) TR199900951T2 (et)
UA (1) UA46762C2 (et)
WO (2) WO1998018325A1 (et)
YU (1) YU42397A (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
CA2444787A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
DE60210283T2 (de) 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
KR950010891A (ko) * 1993-10-15 1995-05-15 피터 지. 스트링거 내성 종양을 치료하는 방법
ZA951497B (en) * 1994-03-02 1996-08-23 Lilly Co Eli Orally administerable pharmaceutical formulations
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol

Also Published As

Publication number Publication date
HUP9701778A3 (en) 1999-06-28
HUP9701777A2 (hu) 1999-06-28
SG83672A1 (en) 2001-10-16
SI0839532T1 (en) 2003-10-31
CA2219070A1 (en) 1998-04-30
DK1369115T3 (da) 2007-01-02
NO974972L (no) 1998-05-04
CN1182591A (zh) 1998-05-27
IL122025A (en) 2003-01-12
GB2318733A (en) 1998-05-06
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
DE69721692T2 (de) 2004-03-25
CH691847A5 (fr) 2001-11-15
GEP20032910B (en) 2003-03-25
GR970100409A (el) 1998-06-30
SG72765A1 (en) 2000-05-23
WO1998018449A1 (en) 1998-05-07
FR2756490A1 (fr) 1998-06-05
IL122025A0 (en) 1998-03-10
ATE338551T1 (de) 2006-09-15
EA200100716A1 (ru) 2002-06-27
ATE239475T1 (de) 2003-05-15
BR9712703A (pt) 1999-10-26
ES2197312T3 (es) 2004-01-01
US6303634B1 (en) 2001-10-16
CH693820A5 (fr) 2004-02-27
IT1298470B1 (it) 2000-01-10
SK287047B6 (sk) 2009-10-07
AU5005697A (en) 1998-05-22
AU4364897A (en) 1998-05-07
CZ341297A3 (cs) 1998-05-13
SI1369115T1 (sl) 2006-12-31
GB9722796D0 (en) 1997-12-24
FR2755014B1 (fr) 1999-02-05
GB9722801D0 (en) 1997-12-24
NZ329042A (en) 1999-08-30
CN1182590A (zh) 1998-05-27
LV12353B (en) 2000-02-20
DE69736644T2 (de) 2007-10-25
HK1010495A1 (en) 1999-06-25
FR2756490B1 (fr) 2003-06-20
HUP9701778A2 (hu) 1999-01-28
AR010538A1 (es) 2000-06-28
EE03663B1 (et) 2002-04-15
EP0839532A1 (en) 1998-05-06
BG63841B1 (bg) 2003-03-31
NL1007386C2 (nl) 1998-05-14
TR199900951T2 (xx) 1999-07-21
BE1011382A5 (fr) 1999-08-03
PT839532E (pt) 2003-09-30
PT1369115E (pt) 2006-12-29
ES2271476T3 (es) 2007-04-16
RO120813B1 (ro) 2006-08-30
EA199900431A1 (ru) 1999-10-28
IE970773A1 (en) 2000-02-09
ES2135343A1 (es) 1999-10-16
ITMI972433A1 (it) 1999-04-29
BE1011381A5 (fr) 1999-08-03
AU5005197A (en) 1998-05-22
CZ300261B6 (cs) 2009-04-01
AU4364797A (en) 1998-05-07
DK0839532T3 (da) 2003-08-25
EP0839533A1 (en) 1998-05-06
NO322468B1 (no) 2006-10-09
IL122026A0 (en) 1998-03-10
CA2219070C (en) 2007-12-18
GR970100408A (el) 1998-06-30
SI20107A (sl) 2000-06-30
FR2755014A1 (fr) 1998-04-30
JPH10147529A (ja) 1998-06-02
LU90157B1 (fr) 1998-06-02
ES2135342B1 (es) 2000-05-16
AU731388B2 (en) 2001-03-29
EE9900162A (et) 1999-12-15
GB2318734A (en) 1998-05-06
NO974972D0 (no) 1997-10-28
EP1369115B1 (en) 2006-09-06
UA46762C2 (uk) 2002-06-17
JPH10147530A (ja) 1998-06-02
GR1003189B (el) 1999-09-01
NO974973D0 (no) 1997-10-28
SK55999A3 (en) 2000-06-12
GB2318734B (en) 1999-12-01
AP9901494A0 (en) 1999-03-31
YU42397A (sh) 2000-10-30
MY121623A (en) 2006-02-28
GB9911557D0 (en) 1999-07-21
BG103369A (en) 2000-05-31
US20020019418A1 (en) 2002-02-14
CZ341197A3 (cs) 1998-05-13
EA002054B1 (ru) 2001-12-24
DE69721692D1 (de) 2003-06-12
EP0839532B1 (en) 2003-05-07
WO1998018325A1 (en) 1998-05-07
ITMI972434A1 (it) 1999-04-29
IE970772A1 (en) 2000-02-09
HUP9701777A3 (en) 1999-07-28
IS5035A (is) 1999-04-27
LV12353A (lv) 1999-10-20
NL1007387C2 (nl) 1998-05-14
EP1369115A1 (en) 2003-12-10
AR013864A1 (es) 2001-01-31
MX9708341A (es) 1998-08-30
EA006083B1 (ru) 2005-08-25
CA2219377A1 (en) 1998-04-30
ES2135342A1 (es) 1999-10-16
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
AP971A (en) Use of raloxifene in preventing breast cancer.
AU712800B2 (en) Method of increasing testosterone
AU701701B2 (en) Methods of inhibiting breast disorders
US20040167170A1 (en) Methods of preventing breast cancer
AU2004231254B8 (en) Methods of preventing breast cancer
IL152080A (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for preventing breast cancer
KR100522646B1 (ko) 유방암의예방방법
NZ292017A (en) Use of raloxifene to treat endometrial cancer
MXPA97008341A (en) Procedures to prevent the cancer of m
PL190551B1 (pl) Zastosowanie chlorowodorku raloksyfenu